Schedule III cannabis would open FDA pathways, not legalization

December 13, 2025

Trump-backed cannabis rescheduling to Schedule III could expand FDA-style trials for cannabinoid drugs and shift advantages toward pharma and larger firms.

Search

RECENT PRESS RELEASES

Portland groups challenge proposal to divert climate action funds to hire police

SWI Editorial Staff2025-12-13T13:06:24-08:00December 13, 2025|

These Three Metrics Show BTC Found Strong Support Near $80,000

SWI Editorial Staff2025-12-13T13:05:36-08:00December 13, 2025|

Trump expected to sign EO to reclassify marijuana as soon as Monday, CNBC says

SWI Editorial Staff2025-12-13T13:04:57-08:00December 13, 2025|

Bombshell cannabis study reveals hidden risks of medical pot that may…

SWI Editorial Staff2025-12-13T13:04:27-08:00December 13, 2025|

Why Rescheduling Cannabis Is a Very Bad Idea

SWI Editorial Staff2025-12-13T13:03:57-08:00December 13, 2025|

Ethereum Price Prediction: Whale Accumulation and ETF Inflows Strengthen Bullish Case—Can

SWI Editorial Staff2025-12-13T13:02:53-08:00December 13, 2025|